Chlorpheniramine Maleate Throat Spray for the Treatment of COVID-19-Induced Acute Viral Pharyngitis: Case Series.
| Autor: | Tesch ML; Research and Development, Dr. Ferrer Biopharma, Hallandale Beach, USA., Dasgupta R; Pulmonary and Critical Care Medicine, Aventura Hospital and Medical Center, Aventura, USA., Khawaja UA; Internal Medicine, Jinnah Medical and Dental College, Karachi, PAK.; Clinical and Translational Research, Larkin Community Hospital, South Miami, USA., Sanchez-Gonzalez M; Health Services Administration, Lake Erie College of Osteopathic Medicine, Bradenton, USA.; Research and Development, Dr. Ferrer Biopharma, Hallandale Beach, USA., Franck R; Medicine and Surgery, Cleveland Clinic Florida, Weston, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Jan 28; Vol. 15 (1), pp. e34310. Date of Electronic Publication: 2023 Jan 28 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.34310 |
| Abstrakt: | Acute viral pharyngitis (AVP) is a common respiratory illness affecting many individuals. Despite symptomatic treatment management of AVP, therapies are lacking to target a broad spectrum of viruses and the inflammatory nature of the disease. Available for many years, Chlorpheniramine Maleate (CPM), is considered a low-cost and safe first-generation antihistamine displaying antiallergic, anti-inflammatory, and as of recently, identified as a broad-spectrum antiviral agent with activity against influenzas A/B viruses and SARS-CoV-2. Efforts have been made to identify repurposed drugs with favorable safety profiles that could significantly benefit the treatment of COVID-19-induced symptoms. The present case series highlights three patients in which a CPM-based throat spray was used to alleviate the symptoms of COVID-19-induced AVP. The CPM throat spray was associated with significant improvements in patient symptoms after approximately three days of use as opposed to the typical five to seven days reported elsewhere. While AVP is a self-limited syndrome and usually improves without pharmaceutical therapy, CPM throat spray may significantly reduce the overall time that the patient has symptoms. Additional clinical studies to evaluate the efficacy of CPM for the treatment of COVID-19-induced AVP are warranted. Competing Interests: Dr. Ferrer owns the intellectual property rights for patents: "Antiviral & Virucidal Nasal Spray Compositions And Related Treatment Methods” (US Patent No. 10,874,650; Issue Date 12/29/2020) in the USA. (Copyright © 2023, Tesch et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|